In Q3 of fiscal 2024, the quarter ended Sep 30, 2024, HST Global, Inc. used $18,549 of cash from operations, down 324.6% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2024
|
Q3 FY2024
Sep 30, 2024
|
Q2 FY2024
Jun 30, 2024
|
Q1 FY2024
Mar 31, 2024
|
Q4 FY2023
Dec 31, 2023
|
Q3 FY2023
Sep 30, 2023
|
Q2 FY2023
Jun 30, 2023
|
Q1 FY2023
Mar 31, 2023
|
Q4 FY2022
Dec 31, 2022
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Operating cash flow |
-0
-90.8%
|
-0
-324.6%
|
0
-31.4%
|
-0
+14.1%
|
-0
-19.3%
|
-0
+4.8%
|
0
+667.2%
|
-0
-436.4%
|
-0
+0.2%
|
| Investing | |||||||||
| Investing cash flow |
—
|
—
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Financing | |||||||||
| Financing cash flow |
0
+114.3%
|
0
+487.8%
|
-0
+42.8%
|
0
-15.8%
|
0
+11.1%
|
0
-10.0%
|
-0
-596.1%
|
0
+442.9%
|
0
+4.6%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HSTC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Virginia Beach, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 797564
- Former names
- NT HOLDING CORP. (until Mar 31, 2009); ABSS CORP (until Aug 12, 2004); UNICO INC (until May 22, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.